Subo Biomedical Completes RMB 50 Million Series C1 Financing Led by Qingke Asset Management, with Qingke Capital as Exclusive Financial Advisor

VCBeat (WeChat ID: vcbeat) has learned that on March 19, 2019, Jiangsu Superbio Life Science Co., Ltd. (“Superbio”), a leading enterprise applying biotechnology to the public safety sector, completed its C1 round of financing amounting to RMB 50 million. This round was led by Beijing Zero2ipo Investment Management Co., Ltd., with Zero2ipo Capital continuing to serve as the exclusive financial advisor. In 2017, Zero2ipo Capital had previously assisted Superbio in completing its Series B financing.

Jiangsu Superbio Life Science Co., Ltd. was established in 2011, entering the market through DNA technology and committed to making society safer through forensic science. The company’s core business comprises two main segments: judicial appraisal services and public security technical solutions. It has since evolved into a high-tech enterprise specializing in R&D and testing services within the gene sequencing industry.

According to VCBeat, Superbio’s latest round of financing will be primarily allocated to two key areas. First, the company will deepen its provision of comprehensive forensic appraisal services while leveraging mobile internet technology innovations to build an integrated industry-chain management cloud platform. Second, it will focus on delivering one-stop solutions for public security technologies, offering professional, customized services tailored to diverse business needs and application scenarios.

Cai Jun, Executive Director of Beijing Zero2ipo Investment Management Co., Ltd., stated that Jiangsu Superbio Life Science CO.,Ltd. has matched its experimental testing technologies in the life sciences sector and its marketing service models in the healthcare services sector with the technical service demands of the public security and judicial fields, achieving a “dimensional reduction strike.” The team’s high-efficiency execution has driven rapid growth in both business operations and financial performance, positioning the company as the leader in this sector.

The application and popularization of new biotechnologies in the field of public safety remain relatively conservative, with the industry as a whole still in its early stages of development. In particular, these technologies hold significant potential for application and value in areas such as forensic science and police technology.

As national policy documents continue to be issued to guide the specialization, standardization, and normalization of judicial appraisal, the role of new technologies in promoting innovative development and enhancing the efficiency of judicial administration has become increasingly prominent. Meanwhile, the strong demand for mastering new technologies among grassroots public security organs at the district and county levels, coupled with the emergence of high-tech crimes, has placed new demands on their technical capabilities. New technologies are becoming a new growth driver for solving criminal cases.

Jiangsu Superbio Life Science Co., Ltd. deeply explores the needs of clients within the public security system, adheres to a research and development philosophy centered on high technology and high standards, and continuously develops cutting-edge detection technologies and products. By consistently providing high-quality, premium services, the company drives the development of the public safety industry—a commitment that reflects both an industry trend and a corporate mission.

Yu Jurong, Partner at Zero2ipo Capital, stated that as markets in first-tier cities become saturated, the downward expansion of channels for mature biomedical technology services and their application in new scenarios will become the new normal for industry development. In the field of public security and justice, we have observed a significant gap between central policy formulation—such as “forensic evidence science” and the principle of “prioritizing physical evidence over confessions”—and local implementation, largely due to insufficient local development levels. This gap is difficult to bridge in the short term. We are honored to have continuously assisted Jiangsu Superbio Life Science Co., Ltd. in securing capital support. Throughout this process, we have witnessed the team’s sustained capacity for self-renewal and iterative development. We are highly optimistic about Jiangsu Superbio’s future as a platform company in the field of forensic evidence science.

Currently, as a high-tech enterprise focused on research and testing services in the gene sequencing industry, Jiangsu Superbio Life Science Co., Ltd. serves public safety management needs through its “3+4” model. The company has established three major service platforms (the Public Security Technical Laboratory System, the Judicial Appraisal Institute System, and the Cloud Service System) and four major technical support platforms (the Cloud Training System, the Individual Equipment System, the Rapid Testing Equipment System, and the Forensic Laboratory System), providing systematic solutions for public security clients.

In terms of market channels, Jiangsu Superbio Life Science Co., Ltd. has established a comprehensive national network for forensic identification services, achieving coverage across 31 provinces, 311 prefecture-level cities, and 1,875 districts and counties in China, with a market coverage rate of 66%. Meanwhile, the company is also expanding into overseas markets. In the realm of high-end instrument manufacturing, Jiangsu Superbio has joined forces with Suyuan Genomics to jointly launch the world’s first 8-color fluorescent first-generation sequencer, breaking the long-standing monopoly held by foreign enterprises in China and significantly enhancing industry efficiency.

Yang Min, Managing Partner of Zero2ipo Group, stated that a family fund under the management of Zero2ipo Asset Management led the investment in Jiangsu Superbio Life Science Co., Ltd., and integrated a new fund with a background in the public safety industry to participate in the follow-on investment. Zero2ipo Asset Management will uphold an open and cooperative attitude, remain committed to identifying top-tier companies in niche sectors, leverage the strengths of various platforms to invest in high-growth business tracks, and focus on facilitating the long-term development of enterprises. Managing dozens of family industry funds, Zero2ipo Asset Management assists family businesses in seeking industrial consolidation opportunities, optimizing industrial layouts, achieving new wealth growth points, and attaining ideal financial returns.

Currently, Jiangsu Superbio Life Science CO.,Ltd. is undergoing its Series C2 financing round.

Zero2ipo Asset Management

Zero2ipo Asset Management is a specialized asset management platform under the Zero2ipo Group, serving listed companies and family enterprises. Currently, Zero2ipo Asset Management oversees dozens of industrial funds for listed companies and family industrial funds, with assets under management reaching RMB 20 billion. Leveraging Zero2ipo Group’s profound understanding of China’s private equity industry and its comprehensive services—including research, conferences, consulting, and investment—Zero2ipo Asset Management adopts an active management approach to uncover corporate and market value, thereby realizing the philosophy of value investing.

Zero2ipo Capital

Zero2ipo Capital is a leading new-type boutique investment bank in China, dedicated to serving innovative enterprises with high growth potential in the new economy. It has successfully assisted companies and investment institutions in completing nearly 300 transactions, including private equity financing, mergers and acquisitions, IPOs, PIPE investments, and privatizations, covering all stages of corporate development. The healthcare team at Zero2ipo Capital focuses on the following key areas: 1) Medical devices, represented by in vitro diagnostics (IVD); 2) Leading opportunities and technological innovations in biopharmaceuticals; 3) Innovation in healthcare services, particularly single-disease specialty opportunities; 4) Healthcare industrial internet and healthcare informatization.